RNS Number : 3138Z
Abzena PLC
26 May 2016
Abzena plc
Notice of full year results
Cambridge, UK, 26 May 2016 - Abzena plc (AIM: ABZA, 'Abzena' or the
'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical
products, will be publishing its full year results for the year to 31 March 2016 on Tuesday, 14 June 2016.
A presentation for analysts will be held at 11.30am on 14 June 2016 at the offices of Instinctif
Partners (65 Gresham Street, London EC2V 7NQ).
Enquiries:
|
Abzena plc
John Burt, Chief Executive Officer Julian Smith, Chief Financial
Officer
|
+44 1223 903498
|
|
Cenkos Securities (Nominated Adviser and Broker)
Christopher Golden / Ivonne Cantu
|
+44 20 7397 8900
|
|
N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong
|
+44 20 7496 3000
|
|
Instinctif Partners
Melanie Toyne Sewell / Rozi Morris
|
+44 20 7457 2020
abzena@instinctif.com
|
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the
development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The
Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small
biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products that have
been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™
and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or
royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its principal sites in Cambridge
(UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
§ Immunogenicity assessment,
protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for
manufacture.
§ Contract process development
and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell
therapy products, for preclinical and clinical studies.
§ Proprietary site-specific
conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of
biopharmaceuticals.
§ Contract chemistry and
bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORDMGZKDKFGVZM